AtriCure Shares Plunge to New 1-Year Low

Medical device company's stock drops amid analyst downgrades and price target cuts

Mar. 30, 2026 at 3:34pm

Got story updates? Submit your updates here. ›

Shares of AtriCure, Inc. (NASDAQ:ATRC), a leading manufacturer of surgical ablation devices for treating atrial fibrillation, have fallen to a new 52-week low of $28.18 amid a series of analyst downgrades and price target cuts.

Why it matters

AtriCure's stock decline reflects broader concerns about the company's growth prospects and competitive positioning in the rapidly evolving cardiac device market. The downgraded analyst ratings and reduced price targets signal potential challenges the company may face in the near term.

The details

Several Wall Street analysts have recently lowered their ratings and price targets for AtriCure. Zacks Research downgraded the stock from 'strong buy' to 'hold', while Needham & Company, UBS Group, and Canaccord Genuity all cut their price targets, citing factors such as increased competition and potential headwinds in the company's core markets.

  • AtriCure's stock reached a new 52-week low of $28.18 on March 30, 2026.
  • The company's shares closed at $28.54 on the same day, down 1.2% from the previous close.

The players

AtriCure, Inc.

A medical device company focused on the development, manufacture, and marketing of innovative therapies to treat atrial fibrillation and related conditions.

Got photos? Submit your photos here. ›

What they’re saying

“We must downgrade AtriCure to a 'hold' rating due to increased competition and potential headwinds in the company's core markets.”

— Zacks Research Analyst

“While AtriCure remains a leader in surgical ablation devices, we are lowering our price target to $45 due to concerns about the company's growth trajectory.”

— Needham & Company Analyst

What’s next

Investors will be closely watching AtriCure's upcoming earnings report and any updates from the company on its strategy to address the competitive challenges it faces.

The takeaway

AtriCure's stock decline highlights the volatility and competitive pressures in the medical device industry, underscoring the importance of closely monitoring market trends and analyst sentiment when evaluating investment opportunities.